Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037440
Status:
COMPLETED
Last Update Posted:
2014-12-03
First Post:
2002-05-16
Brief Title:
Genetic Epidemiology of Change in CVD Risk Factors
Sponsor:
The University of Texas Health Science Center Houston
Organization:
The University of Texas Health Science Center Houston
Study Overview
Official Title:
Genetic Epidemiology of Change in CVD Risk Factors HL70568-1
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To extend knowledge of the genetic factors affecting the course of cardiovascular disease risk factor development over a substantial portion of an individuals lifetime
Detailed Description:
BACKGROUND
While the onset of symptomatic cardiovascular disease CVD typically occurs in middle age or later the development of the underlying pathology is clearly a long-term process and early-state lesions having been identified at autopsy even in children Understanding the course of CVD risk development from childhood into middle age will clearly be valuable both in understanding the pathology of CVD and in targeting preventive measures most effectively Furthermore while genetic factors are agreed to play a significant role in the development of CVD most genes contributing to interindividual variation in CVD risk will have relatively small effects on risk for any given individual even though their aggregate effects contribute significantly to CVD risk in the overall population Relatively little is known about the effects of genetic variants on the course of CVD risk factor development in individuals over time The Bogalusa Heart Study BHS which began in 1973 as a study of CVD risk factors in children but evolved to cover the development of CVD risk factors from childhood into early middle age offers an unparalleled resource for investigating the genetic factors influencing within-individual changes over time in quantitative factors such as serum lipids and blood pressure related to CVD risk
DESIGN NARRATIVE
Approximately 1500 individuals who were examined in the BHS on at least three separate occasions over a period of up to 20 years and who consented to participate in studies of genetic factors influencing CVD risk will have genotypes measured at selected loci either known or strongly suspected to affect interindividual variation in CVD risk Longitudinal multilevel regression will be used to measure the effects of variation at these loci on quantitative CVD risk factor profiles within individuals and to determine whether some gene effects on CVD risk variation are age-dependent
While the onset of symptomatic cardiovascular disease CVD typically occurs in middle age or later the development of the underlying pathology is clearly a long-term process and early-state lesions having been identified at autopsy even in children Understanding the course of CVD risk development from childhood into middle age will clearly be valuable both in understanding the pathology of CVD and in targeting preventive measures most effectively Furthermore while genetic factors are agreed to play a significant role in the development of CVD most genes contributing to interindividual variation in CVD risk will have relatively small effects on risk for any given individual even though their aggregate effects contribute significantly to CVD risk in the overall population Relatively little is known about the effects of genetic variants on the course of CVD risk factor development in individuals over time The Bogalusa Heart Study BHS which began in 1973 as a study of CVD risk factors in children but evolved to cover the development of CVD risk factors from childhood into early middle age offers an unparalleled resource for investigating the genetic factors influencing within-individual changes over time in quantitative factors such as serum lipids and blood pressure related to CVD risk
DESIGN NARRATIVE
Approximately 1500 individuals who were examined in the BHS on at least three separate occasions over a period of up to 20 years and who consented to participate in studies of genetic factors influencing CVD risk will have genotypes measured at selected loci either known or strongly suspected to affect interindividual variation in CVD risk Longitudinal multilevel regression will be used to measure the effects of variation at these loci on quantitative CVD risk factor profiles within individuals and to determine whether some gene effects on CVD risk variation are age-dependent
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL070568 | NIH | None | httpsreporternihgovquickSearchR01HL070568 |